Provided by Tiger Trade Technology Pte. Ltd.

Relay Therapeutics

19.44
-0.2600-1.32%
Post-market: 19.500.0600+0.31%19:56 EDT
Volume:2.97M
Turnover:58.13M
Market Cap:4.26B
PE:-12.42
High:20.17
Open:19.92
Low:19.18
Close:19.70
52wk High:21.27
52wk Low:3.43
Shares:219.14M
Float Shares:145.00M
Volume Ratio:1.41
T/O Rate:2.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5651
EPS(LYR):-1.6113
ROE:-36.77%
ROA:-22.88%
PB:4.79
PE(LYR):-12.06

Loading ...

Relay Therapeutics Price Target Raised to $29.00/Share from $28.00 by HC Wainwright & Co.

Dow Jones
·
Aug 20

U.S. Research Roundup-Amgen, Analog Devices, Moderna

Reuters
·
Aug 20

Relay Therapeutics (RLAY) Stock May Be Fully Valued After A 7x Run

Simply Wall St.
·
Aug 20

Relay Therapeutics CFO Thomas Catinazzo Disposes of 17,717 Common Shares Worth $349,703.58

Reuters
·
Aug 19

Relay Therapeutics price target raised to $31 from $28 at JPMorgan

TIPRANKS
·
Aug 16

Analysts Offer Insights on Healthcare Companies: Mediwound (MDWD) and Relay Therapeutics (RLAY)

TIPRANKS
·
Aug 14

Relay Therapeutics Price Target Raised to $26.00/Share from $21.00 by Citizens

Dow Jones
·
Aug 10

Relay Therapeutics price target raised to $26 from $21 at Citizens

TIPRANKS
·
Aug 10

Analysts Offer Insights on Healthcare Companies: Xenon (XENE), Relay Therapeutics (RLAY) and Amylyx Pharmaceuticals Inc (AMLX)

TIPRANKS
·
Aug 10

Relay Therapeutics is Maintained at Overweight by Barclays

Dow Jones
·
Aug 08

CytomX Q2 Revenue Misses, Partly Hurt by Lower Research Activities in the Astellas Collaboration

Reuters
·
Aug 07

Relay Therapeutics Q2 2026 earnings: Clinical spending rises with cash runway into 2029

TradingKey
·
Aug 07

Relay Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 07

Earnings Flash (RLAY) Relay Therapeutics Posts Q2 Loss $0.41 per Share, vs. FactSet Est of $0.39 Loss

MT Newswires Live
·
Aug 07

Relay Therapeutics Amends TD Securities Equity Distribution Deal, Lifts Potential Sales to $462.98 Million

Reuters
·
Aug 07

Relay Therapeutics - Increases At-the-Market Offering Program to $462.98 Mln - SEC Filing

THOMSON REUTERS
·
Aug 07

Relay Therapeutics Q2 Revenue Misses Estimates on Higher R&D Expenses; Net Loss Widens

Reuters
·
Aug 07

Relay Therapeutics Q2 EPS $(0.41) Misses $(0.39) Estimate, Sales $350.000K Miss $872.727K Estimate

Benzinga Earnings
·
Aug 07

Relay Therapeutics Q2 Net Income USD -83.707 Million Vs. IBES Estimate USD -74.2 Million

Reuters
·
Aug 07

Relay Therapeutics Q2 Operating Expenses USD 91.174 Million

THOMSON REUTERS
·
Aug 07